Vectors for correcting pathogenic mutations in LMNA cardiomyopathy and their applications
By delivering specific sgRNAs through the ABE system and AAV vector, precise editing of the LMNA c.1621C>T mutation was achieved, solving the treatment challenge of LMNA cardiomyopathy, improving mutation correction efficiency, and reducing the bystander effect.
Patent Information
- Application Number
- CN202310774801.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-28
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-06-28
AI Technical Summary
Currently, there is a lack of precise and effective treatments to correct cardiomyopathy caused by LMNA gene mutations, especially dilated cardiomyopathy caused by LMNA c.1621C>T mutations.
Using the single-base editor ABE system, specific sgRNAs and segmented ABE protein elements were designed and delivered to cardiomyocytes via AAV vectors to achieve precise editing of the LMNA c.1621C>T mutation.
It improves the correction efficiency of LMNA c.1621C>T mutation, reduces the bystander effect, and provides a precise treatment method for LMNA cardiomyopathy.
Smart Images

Figure CN116875597B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of genetic engineering technology, and in particular to vectors for correcting pathogenic mutations in LMNA cardiomyopathy and their applications. Background Technology
[0002] 1. CRISPR-Cas9 immune system
[0003] The CRISPR-Cas9 system consists of two parts: CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and Cas9 (CRISPR-associated protein 9). CRISPR is a cluster of regularly spaced short palindromic repeat DNA sequences, and Cas9 is a nuclease. This system was discovered in the bacterial immune system. When bacteria encounter bacteriophages or foreign plasmids, they can cut a sequence from the viral gene or foreign plasmid and integrate it into the CRISPR locus in their own genome. The CRISPR sequence can be transcribed into crRNA (Cas-related RNA), and simultaneously, a trans-activating crRNA is transcribed into the genome. The crRNA and tracrRNA form a double-stranded RNA through base complementarity and then form a complete complex with the Cas9 protein. When exogenous DNA invades again, the tracrRNA-crRNA-Cas9 complex scans the exogenous DNA and, guided by crRNA, locates the site complementary to the crRNA. The crRNA forms a double strand with the complementary sequence, while the other strand remains free. At this point, Cas9 performs its endonuclease function to cut the exogenous DNA into a double strand, causing a double-strand break (DSB), thereby preventing the invasion of exogenous DNA (Horvath P et al. CRISPR / Cas, the immune system of bacteria and archaea. Science. 2010 Jan 8; 327(5962):167-70).
[0004] One important application of CRISPR-Cas9 is gene editing. Based on CRISPR-Cas9, research has shown that tracrRNA and crRNA can be linked into a single-stranded guide RNA (sgRNA). By artificially designing an sgRNA, it can also form a complex with Cas9 and guide the complex to target a specific location in the genome for double-strand cutting (Jinek M et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012 Aug 17; 337(6096):816-21). After a DNA double-strand break, the cell initiates two repair mechanisms: non-homologous end joining (NHEJ) and homologous recombination (HDR). When NHEJ repair occurs, small insertions or deletions are usually produced, thereby disrupting the function of the target gene. When HDR repair occurs, the target gene can be selectively modified by providing an exogenous DNA template, but gene editing relying on HDR is less efficient (Haber JE et al. Repairing a double-strand chromosome break by homologous recombination: revisiting Robin Holliday's model. Philos Trans R Soc Lond BBiol Sci. 2004 Jan 29; 359(1441):79-86).
[0005] 2. ABE Single Base Editing System
[0006] The double-strand cleavage of Cas9 is accomplished by two domains. Mutation of one of these domains can generate Cas9 (nickase Cas9, nCas9) with single-strand cleavage function. When the nCas9 protein is fused with the artificially engineered adenine deaminase TadA, TadA-nCas9, guided by sgRNA, locates to the target sequence in the genome. The sgRNA forms a double strand with a complementary region on the genome, while the other strand remains in a single-stranded free state. TadA deaminates adenine (A) within a certain range on the free strand, converting it to creatinine (I). During subsequent DNA replication, I is treated as G, thus achieving the A·T>G·C conversion (Gaudelli NM et al. Programmable base editing of A·Tto G·C in genomic DNA without DNA cleavage. Nature. 2017 Nov 23; 551(7681):464-471). This gene editing tool is called an adenine single-base editor (ABE). Compared to traditional CRISPR-Cas9 gene editing tools, ABE forgoes double-strand cutting activity, thus avoiding unpredictable DNA insertion / deletion mutations generated by NHEJ. Instead, TadA can precisely achieve single-base directional conversion, combining both efficiency and precision.
[0007] 3. SpCas9 mutants with reduced PAM sequence restriction
[0008] CRISPR-Cas systems typically require the recognition of a specific motif, called a prototype spacer adjacent motif (PAM), before they can edit DNA. The classic PAM sequence for Streptococcus pyogenes Cas9 (SpCas9) is NGG, where N is any base and G is guanine. The PAM sequence limits the editable sequences within the genome. To mitigate this limitation, Hiroshi et al. reported a SpCas9 variant that recognizes the NG PAM, named SpCas9-NG, or NG for short (Nishimasu H et al. Engineered CRISPR-Cas9 nuclease with expanded targeting space. Science. 2018 Sep 21; 361(6408):1259-1262). Walton et al. used molecular evolution to modify SpCas9, designing a series of SpCas9 variants that recognize a wider range of PAMs. One variant, SpG, was developed that can target NG PAM; and through further optimization, a nearly PAM-free SpCas9 variant, named SpRY, was developed that can target NRN / NYN PAM, greatly expanding the potential applications of gene editing (Walton RT et al. Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. Science. 2020 Apr 17; 368(6488):290-296).
[0009] 4. In vivo delivery of ABE single-base edited dual AAV system
[0010] AAV (Adeno-associated virus) is a non-pathogenic, single-stranded DNA virus commonly used as a vector for in vivo gene delivery. The AAV viral capsid contains approximately 60 protein subunits, including three major structural proteins: VP1, VP2, and VP3. These protein subunits combine to form a symmetrical hollow capsid containing the AAV DNA genome. The AAV genome is typically small, only 4.7 kb (Wu Z et al. Effect of genome size on AAV vector packaging. Mol Ther. 2010 Jan; 18(1):80-6).
[0011] AAV viruses are widely used in gene therapy, with advantages including high transfection rate, low immunogenicity, and effective delivery to various tissues and organs. However, when using AAV vectors, the actual gene-carrying region is only about 4.7kb due to the limitation of genome loading capacity. The ABE system using SpCas9 mutants exceeds the size limit and is difficult to pack into a single AAV. To solve this problem, researchers split the protein elements of the ABE system into two parts, each fused with an inteptide, and packaged into two AAVs respectively. When the two AAVs enter the same cell, the two protein segments are expressed, and the inteptide mediates trans-protein splicing to recombine into the complete ABE protein (Levy JM et al. Cytosine and adenine baseediting of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat Biomed Eng. 2020 Jan; 4(1):97-110).
[0012] 5. LMNA-associated dilated cardiomyopathy
[0013] Dilated cardiomyopathy (DCM) is a heart disease characterized by left ventricular dilation and systolic dysfunction, which can lead to heart failure and sudden cardiac death in severe cases. Studies have shown that 30-40% of DCM cases are caused by autosomal gene mutations (Merlo M et al. Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail. 2018 Feb; 20(2):228-239), of which 5-10% of cases are associated with LMNA gene mutations (Zahr HC et al. Exploring the Crosstalk Between LMNA and Splicing Machinery Gene Mutations in Dilated Cardiomyopathy. Front Genet. 2018 Jul 9; 9:231).
[0014] The LMNA gene encodes the nuclear laminin Lamin-A / C, a major component of the nuclear cytoskeleton. Because Lamin-A / C plays a role in regulating multiple processes, including nuclear biomechanics, chromatin organization, epigenetic landscape, and transcriptional activity (de Leeuw R et al. Nuclear Lamins: Thin Filaments with Major Functions. Trends Cell Biol. 2018 Jan; 28(1):34-45), it is difficult to develop precise and effective treatments for LMNA-related DCM targeting a single pathological mechanism.
[0015] The LMNA c.1621C>T gene mutation is a widely reported pathogenic mutation in dilated cardiomyopathy (DCM) patients (Yang L et al. The LMNA p.R541C mutation causes dilated cardiomyopathy in human and mice. Int J Cardiol. 2022 Sep 15; 363:149-158). Currently, there are no effective treatments for cardiomyopathy associated with this mutation. The challenges of using ABE to correct the LMNA c.1621C>T gene mutation are ① how to avoid the bystander effect of ABE editing of LMNA c.1619T, and ② how to improve the efficiency of ABE in correcting the LMNA c.1621C>T gene mutation. This invention, through extensive research and development, provides an AAV single-base editing vector and its application that overcomes the above challenges and uses ABE technology to correct the LMNA c.1621C>T mutation in vivo, thereby treating cardiomyopathy caused by this mutation. Summary of the Invention
[0016] The purpose of this invention is to provide a vector for correcting pathogenic mutations in LMNA cardiomyopathy and its application, thereby addressing the current lack of precise and effective treatments for cardiomyopathy caused by LMNA gene mutations.
[0017] In a first aspect, the present invention provides an sgRNA comprising (1) sgRNA1, the nucleotide sequence of which is shown in SEQ ID NO.1, and (2) scaffold RNA linked to the 3' end of sgRNA1; wherein the sequence of the scaffold RNA is shown in SEQ ID NO.2.
[0018] In some embodiments of the first or other aspects, the target site binding region sequence of the sgRNA1 of the present invention is an exon 10 sequence of the LMNA gene containing the c.1621C>T mutation in humans or mice; wherein the human sequence is shown in SEQ ID NO. 3, and the mouse sequence is shown in SEQ ID NO. 4.
[0019] In some embodiments of the first or other aspects, the sgRNA described in this invention is used to correct pathogenic mutations in the LMNA gene.
[0020] In some embodiments of the first or other aspects, the sgRNA described in this invention is used in the preparation of a drug for treating dilated cardiomyopathy.
[0021] In a second aspect, the present invention provides a set of single-base editing plasmid vectors, the single-base editing plasmid vectors comprising (1) a gene expressing sgRNA as described above driven by a U6 promoter, and (2) a gene expressing an adenine single-base editor (ABE).
[0022] In a third aspect, the present invention provides a set of single-base editing AAV vectors, wherein the single-base editing AAV vector comprises (1) a gene expressing sgRNA as described above driven by a U6 promoter, (2) a gene expressing an adenine single-base editor (ABE), and (3) a cardiophilic AAV capsid; wherein the cardiophilic AAV capsid is selected from one or more of AAV2i8, AAV1, AAV6, AAV8, AAV9, and MyoAAV.
[0023] In some embodiments of the second and third or other aspects, the vector of the present invention is composed of two different vectors, (1) one vector containing a promoter, a TadA mutant, an nSpCas9 mutant N-terminus, and a coding sequence for intein N, and (2) the other vector containing a promoter, intein C, an nSpCas9 mutant C-terminus, and the sgRNA sequence described in the first aspect.
[0024] In some embodiments of the second, third, or other aspects, the promoter included in the vector of the present invention comprises one or more of the following promoters: CMV, CASI, Tnt4, Myl2, and U6; wherein the CMV promoter sequence is shown in SEQ ID NO. 5, the CASI promoter sequence is shown in SEQ ID NO. 6, the Tnt4 promoter sequence is shown in SEQ ID NO. 7, the Myl2 promoter sequence is shown in SEQ ID NO. 8, and the U6 promoter sequence is shown in SEQ ID NO. 9.
[0025] In some embodiments of the second and third aspects or other aspects, the TadA mutant contained in the vector of the present invention includes one of TadA7.10 or TadA8e, preferably TadA8e; wherein the coding nucleic acid sequence of TadA7.10 deaminase is shown in SEQ ID NO.10, and the coding sequence of TadA8e is shown in SEQ ID NO.11.
[0026] In some embodiments of the second, third, or other aspects, the vector of the present invention contains an nSpCas9 mutant comprising one or more of the nSpG, nNG, or nSpRY genes; wherein the N-terminal coding sequence of nSpG is shown in SEQ ID NO. 12, and the C-terminal coding sequence of nSpG is shown in SEQ ID NO. 13; the N-terminal coding sequence of nNG is shown in SEQ ID NO. 14, and the C-terminal coding sequence of nNG is shown in SEQ ID NO. 15; the N-terminal coding sequence of nSpRY is shown in SEQ ID NO. 16, and the C-terminal coding sequence of nSpRY is shown in SEQ ID NO. 17.
[0027] In some embodiments of the second, third, or other aspects, the vector of the present invention contains an nSpCas9 mutant whose coding sequence is split into N-terminal and C-terminal sequences at the nucleic acid sequences corresponding to amino acid positions 713 and 714; wherein the N-terminal and C-terminal sequences are respectively linked to intein N and intein C sequences, and are recombined into a full-length ABE protein in the cell through an intein trans-splicing process.
[0028] In some embodiments of the second, third, or other aspects, the vector of the present invention is used to correct pathogenic mutations in the LMNA gene.
[0029] In some embodiments of the second, third, or other aspects, the carrier described in this invention is used in the preparation of drugs for treating cardiomyopathy.
[0030] The advantages and positive effects of the vector for correcting LMNA cardiomyopathy pathogenic mutations described in this invention and its application are as follows:
[0031] 1. The single-base editing vector provided by this invention can correct the LMNA c.1621C>T gene mutation, solving the problem of the lack of precise and effective treatment methods for cardiomyopathy caused by LMNA gene mutation.
[0032] 2. The sgRNA1 sequence provided by this invention can reduce the bystander effect at the LMNA c.1619T site and improve the specificity of correcting the LMNA c.1621C>T gene mutation.
[0033] 3. This invention screens out an ABE system based on TadA8e, which can improve the efficiency of correcting LMNA c.1621C>T gene mutations.
[0034] The technical solution of the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. Attached Figure Description
[0035] Figure 1 This is a schematic diagram of the operation of the single-base editing vector of the present invention;
[0036] Figure 2 Software predictions of the editing efficiency of candidate sgRNA sequences at target and bystander sites in this invention; A: Candidate sgRNA sequences and their targeted mouse genome sequences. Target site: c.1621T (green); Bystander sites: c.1613T and c.1619T (red). B: Predicted editing efficiency of sgRNA sequences at target and bystander sites using DeepABE software. DeepABE Score represents absolute editing efficiency; ABE Proportion represents relative editing efficiency;
[0037] Figure 3 This invention relates to the experimentally measured editing efficiency of different sgRNAs at adjacent editing sites in vivo; and the injection of AAV-CMV-TadA7.10-nSpG N-inteinN and AAV-CASI-intein C-nSpG C-U6-sgRNA dual AAV Lmna. c.1621C>T / c.1621C>T Editing efficiency in mouse heart and liver (n=4);
[0038] Figure 4 This invention presents a comparison of the amino acid sequences of ABE7.10 and ABE8e, and a comparison of the editing efficiency of the AAV vector; A: Top: Comparison of differentially expressed amino acid sequences between the TadA7.10 variant, the TadA8e variant, and wild-type TadA (red); Bottom: Comparison of plasmid elements containing ABE7.10 and ABE8e; B: Injection of double AAV with AAV-CMV-TadA7.10-nSpG N-inteinN and AAV-CASI-intein C-nSpG C-U6-sgRNA, and injection of double AAV with AAV-CMV-TadA8e-nSpG N-inteinN and AAV-CASI-intein C-nSpG C-U6-sgRNA. c.1621C>T / c.1621C>T Editing efficiency in mouse heart and liver (n=4). Detailed Implementation
[0039] The technical solution of the present invention will be further described below with reference to the accompanying drawings and embodiments.
[0040] Unless otherwise defined, the technical or scientific terms used in this invention shall have the ordinary meaning as understood by one of ordinary skill in the art to which this invention pertains.
[0041] The term "target site" as used in this invention refers to the mutation site c.1621C>T in the LMNA gene, which is the site that is expected to be edited by the adenine single base editor (ABE).
[0042] The term "bystander site" as used in this invention refers to a site in which one or more adenines other than the target site are present in the binding region of the sgRNA and the target site. These sites are sites where editing by the adenine single base editor (ABE) is not desired.
[0043] In the sequence listing of this invention, n represents the "tag" used in the primers used to distinguish samples during high-throughput sequencing, also known as a barcode, which can be freely selected by high-throughput sequencing technicians as needed.
[0044] The reagents and kits used in this invention are all commercially available.
[0045] Example 1
[0046] In this embodiment, we first designed five sgRNAs targeting the mouse Lmna c.1621C>T mutation site and used Deep Base Editor to predict the editing efficiency of different sgRNAs at the target and bystander sites. Furthermore, we cloned the sgRNAs into a base editor (ABE) vector and conducted in vivo experiments to screen for the optimal sgRNA. The specific implementation method is described below.
[0047] (1) Design sgRNA sequences
[0048] Searching the NCBI database for published mouse Lmna gene sequences, we screened for -NGN near the 3′ end of the complementary strand of the mutation site (c.1621C>T) as the protospacer adjacent motif (PAM) site for sgRNAs, and designed 5 sgRNA sequences (e.g., Figure 2 As shown in Figure A), they were named sgRNA1, sgRNA2, sgRNA3, sgRNA4, and sgRNA5, respectively, and their nucleotide sequences are shown in SEQ ID NO.1 and SEQ ID NO.20-23. An enzyme restriction site sequence AAAC was inserted at the 5′ end of the upstream annealing primer and an enzyme restriction site sequence CACC was inserted at the 5′ end of the downstream annealing primer. The designed sgRNA sequences were then synthesized by a third-party company. Furthermore, we observed that both the target site (c.1621T) and the bystander sites (c.1613T and c.1619T) were located within the editing window (e.g., ...). Figure 2(As shown in Figure A). To select the optimal combination of sgRNA and TadA sequences, we will next use Deep Base Editor to predict base editing efficiency and results.
[0049] (2) Evaluate the editing efficiency of candidate sgRNAs
[0050] Given the significant differences in editing efficiency between base editors and different target sequences, researchers often need to experimentally compare different combinations of base editors and sgRNAs to select the optimal editing strategy. To address this issue, Kim F. Marquart et al. developed a prediction tool called Deep Base Editor based on machine learning algorithms. This tool can accurately predict base editing outcomes for adenine and cytosine base editors (ABE / CBE) (Marquart et al. Predicting base editing outcomes with an attention-based deep learning algorithm trained on high-throughput target library screens. Nat Commun 12, 5114, 2021). The Deep Base Editor was used to predict the editing efficiency and results for five sgRNA sequences, as follows:
[0051] First, select ABE as the base editor type to use. Second, enter the target DNA sequence of interest into the sequence box. The sequence should be longer than 26 nt, as Deep Base Editor uses target sequences 24–26 nt long, including 1–3 nt of the left adjacent sequence, a 20 nt sgRNA binding region, and a 3 nt PAM sequence. Third, submit the entered sequence to the server by clicking the "Submit" button on the webpage.
[0052] The prediction results showed that among the five sgRNA sequences, sgRNA1 was most efficient at editing the target site (c.1621T), least efficient at editing the bystander site (c.1619T), and the c.1613T site was not edited (e.g.). Figure 1 (As shown in B). Given that the predicted results indicate that sgRNA4 and sgRNA5 hardly edit the c.1621T site (as shown in B), Figure 1 As shown in Figure B), we chose sgRNA1-3 for the subsequent vector construction and in vivo experiments.
[0053] (3) Construct the plasmids pAAV-CMV-TadA7.10-nSpG N-inteinN and pAAV-CMV-TadA8e-nSpG N-inteinN.
[0054] The CMV promoter, TadA7.10, and the N-terminal sequence of nSpG were amplified using pCMV-T7-ABEmax(7.10)-nSpG-P2A-EGFP as a template. The sequences are shown in SEQ ID NO.5, SEQ ID NO.10, and SEQ ID NO.12, respectively. Then, the sequence was cloned into pAAV-SMVP-Cas9N using a seamless cloning kit to obtain the pAAV-CMV-TadA7.10-nSpG N-inteinN plasmid.
[0055] The TadA8e sequence was amplified using NG-ABE8e as a template, as shown in SEQ ID NO.11. The TadA7.10 sequence in pAAV-CMV-TadA7.10-nSpG N-inteinN was replaced to obtain pAAV-CMV-TadA8e-nSpG N-inteinN.
[0056] (4) Construction of pAAV-CASI-inteinC-nSpGC-U6-sgRNA vector
[0057] The C-terminal sequence of SpG was amplified using pCMV-T7-ABEmax(7.10)-nSpG-P2A-EGFP as a template, as shown in SEQ ID NO.13. The U6 promoter and scaffold RNA sequence were amplified using pU6-Sp-pegRNA-HEK3_CTT_ins as templates, as shown in SEQ ID NO.9 and SEQ ID NO.2, respectively. Then, the sequence was cloned into pAAV-CASI-Cas9C using a seamless cloning kit to obtain the pAAV-CASI-inteinC-nSpG C-U6-sgRNA plasmid.
[0058] (5) Cloning the sgRNA into the pAAV-CASI-inteinC-nSpGC-U6-sgRNA plasmid
[0059] Since Deep Base Editor predictions indicate that sgRNA1-3 has higher editing efficiency at the c.1621T site than sgRNA4-5, we chose sgRNA1-3 for vector construction and in vivo testing. Based on the already obtained pAAV-CASI-inteinC-nSpGC-U6-sgRNA plasmid, sgRNA1-sgRNA3 need to be inserted into the multiple cloning site of this plasmid, respectively. The specific implementation method is as follows:
[0060] Mix 5 μL of each of the upstream and downstream annealing primers for sgRNA and perform gradient annealing to form a double-stranded sgRNA. The annealing procedure was as follows: (1) 95℃, 5 minutes; (2) 95℃, 2 minutes; (3) 90℃, 2 minutes; (4) 85℃, 2 minutes; (5) 80℃, 2 minutes; (6) 75℃, 2 minutes; (7) 70℃, 2 minutes; (8) 65℃, 2 minutes; (9) 60℃, 2 minutes; (10) 55℃, 2 minutes; (11) 50℃, 2 minutes; (12) 45℃, 2 minutes; (13) 40℃, 2 minutes; (14) 35℃, 2 minutes; (15) 30℃, 2 minutes; (16) 25℃, 2 minutes; (17) 20℃, preservation. The upstream primer sequence is shown in SEQ ID NO.24-26, and the downstream primer sequence is shown in SEQ ID NO.27-29.
[0061] Next, the plasmid pAAV-CASI-intein C-nSpG C-U6-sgRNA was linearized using the restriction endonuclease AarⅠ. The enzyme digestion system is shown below:
[0062]
[0063] The reaction procedure was as follows: incubation at 37°C for 1 hour. The linearized vector was subjected to agarose gel electrophoresis with 1.2% agarose solution. Bands of the target fragment size were excised, and the gel was recovered using a gel recovery kit to determine the concentration.
[0064] The annealing products of the three sgRNAs were ligated into the linearized pAAV-CASI-inteinC-nSpGC-U6-sgRNA plasmid using T4 DNA ligase. The ligation system is shown below:
[0065]
[0066]
[0067] The reaction program was 25°C for 10 minutes. 5 μL of the ligation product was transformed into 50 μL of competent *E. coli* Stbl3 cells, and 500 μL of LB medium was added. The cells were incubated at 37°C for 1 hour, centrifuged at 5000 rpm for 1 minute, and the competent cell pellet was pipetted and evenly spread onto LB agar plates containing ampicillin. The plates were then incubated overnight at 37°C. Several colonies were picked for Sanger sequencing identification. Positive single-clone colonies were expanded and subjected to plasmid extraction using an endotoxin-free plasmid extraction kit to obtain the pAAV-CASI-intein C-nSpG C-U6-sgRNA plasmid containing the inserted sgRNA.
[0068] (6) Preparation of AAV9 virus AAV-CMV-TadA7.10-nSpG N-inteinN, AAV-CMV-TadA8e-nSpG N-inteinN and AAV-CASI-intein C-nSpG C-U6-sgRNA.
[0069] This step involves packaging AAV9 virus using the constructed plasmids pAAV-CMV-TadA7.10-nSpG N-inteinN and pAAV-CMV-TadA8e-nSpG N-inteinN, as well as the pAAV-CASI-intein C-nSpG C-U6-sgRNA plasmid containing inserted sgRNA. The specific implementation method is as follows:
[0070] ① Prepare HEK293 cells. Prepare 10 plates of HEK293 cells for each plasmid to be packaged. Cell density should reach 70-80% on the day of transfection. ② 2-5 hours before transfection, replace the medium with fresh medium (10% FBS, 1% Pen-Strep in DMEM). Add 140 μg of plasmid vector, 140 μg of AAV9-Rep / Cap plasmid, and 320 μg of pHelper to 20 mL of Opti-MEM, mix well, add 2.4 mL of PEI (1 mg / mL), mix again, and incubate at room temperature for 15 minutes. Add 2 mL of the PEI-DNA mixture to each plate and shake thoroughly. ③ 12-18 hours later, replace the medium with serum-free medium (DMEM with 1% Pen-Strep). ④ Continue culturing for 60-72 hours, harvest the cells, transfer them along with the medium to sterile centrifuge tubes, and centrifuge at 2000 rpm for 5 minutes at 4°C. Resuspend the cell pellet in 7 mL of lysis buffer to a final volume of approximately 10 mL. Add 1 μL of totipotent nuclease (≥250 units / μL) to the cell suspension and transfer it to a 50 mL centrifuge tube. Lyse the cells using the following freeze-thaw cycles: -80°C for 30 minutes, 37°C for 30 minutes, -80°C for 30 minutes, and 37°C for 30 minutes. After thawing at 37°C, centrifuge at 4000 rpm for 30 minutes at 4°C. Spread the supernatant on a gradient of iodixanol and perform ultracentrifugation to separate AAV virus particles. ⑥ In a rotary condenser with a molecular weight cutoff of 100 kDa, mix the extracted AAV-containing layer (approximately 4 mL) with 10 mL PBS + 0.001% nonionic surfactant Pluronic F-68 and centrifuge at 5000 × g for 30 minutes at 4°C. Remove the eluent and then add 15 mL of fresh PBS containing F68 (0.001% F68 in the PBS). Repeat the washing process three times. ⑦ Determine the AAV titer by real-time quantitative PCR (RT-qPCR). Aliquot the purified AAV virus solution and store it at -80°C.
[0071] The above steps can be used to prepare AAV9 virus AAV-CMV-TadA7.10-nSpG N-inteinN, AAV-CMV-TadA8e-nSpG N-inteinN, and AAV-CASI-intein C-nSpG C-U6-sgRNA.
[0072] (7) Compare the editing efficiency of sgRNA1-3 in vivo.
[0073] In a published paper (Yang L et al. The LMNA p.R541C mutation causes dilated cardiomyopathy in human and mice. Int J Cardiol. 2022 Sep 15; 363:149-158), a mouse model carrying the homozygous mutation of LMNA c.1621C>T was constructed (using LMNA... c.1621C>T / c.1621C>T (This indicates that) we use this model for in vivo experiments.
[0074] Lmna 1 day after birth c.1621C>T / c.1621C>T Mice were administered double AAV subcutaneous injections (5 × 10⁻⁶) of AAV-CMV-TadA7.10-nSpG N-inteinN and AAV-CASI-intein C-nSpG C-U6-sgRNA. 10 vg / g (vg / g is an abbreviation for vectorgenome per gram body weight, referring to the number of viral vector genomes per gram of body weight, the same below) was used. Mice were fed for another 7 days, after which fresh heart and liver tissues were collected. Genomic DNA was extracted from the heart and liver using a genomic DNA extraction kit and analyzed by amplicon sequencing (AMP-Seq). The specific implementation method is as follows:
[0075] Primer design for high-throughput sequencing library construction at the target site: the nucleotide sequence of upstream primer F is shown in SEQ ID NO.30, and the nucleotide sequence of downstream primer R is shown in SEQ ID NO.31. Next, using genomic DNA as a template, the target DNA fragment was amplified using the following PCR reaction system:
[0076]
[0077] The reaction procedure was as follows: (1) 94℃, 3 minutes; (2) 94℃, 30 seconds; (3) 60℃, 30 seconds; (4) 72℃, 30 seconds, wherein steps (2)-(4) were repeated for 30 cycles; (5) 72℃, 5 minutes; (6) 4℃, for storage. The amplified products were subjected to agarose gel electrophoresis with 1.5% agarose solution. The target fragment bands were excised and recovered using a gel extraction kit. The recovered library was then sent to a third-party company for high-throughput sequencing of the amplified products. The sequencing results were analyzed using CRISPResso2 and plotted using Graphpad Prism software. The results showed that sgRNA1 had the highest editing efficiency at the target site (c.1621T) and the lowest efficiency at the bystander site (c.1619T) in the heart and liver (e.g., [missing information]). Figure 3 As shown in the figure, this is consistent with the predicted results.
[0078] Conclusion: Among the five sgRNAs we designed, sgRNA1 is the optimal choice.
[0079] (8) Comparison of in vivo editing efficiency between adenine base editors ABE7.10 and ABE8e
[0080] To improve the editing efficiency of the adenine base editor (ABE), researchers have continuously engineered various components of ABE, resulting in two editor versions: ABE7.10 and ABE8e. The difference between them lies in the engineered deaminase TadA fused with nSpG: ABE7.10 contains one wild-type TadA and one TadA7.10 variant (e.g., ...). Figure 4 As shown in Figure A), ABE8e contains only one engineered variant of TadA8e with 7 codon optimizations (such as...). Figure 4 (As shown in A). To further improve editing efficiency, we will now compare the in vivo editing efficiency of ABE7.10 and ABE8e. In step (7) of this embodiment, we have already screened sgRNA1 as the optimal sgRNA, so sgRNA1 will be used in all subsequent experiments.
[0081] Lmna 1 day after birth c.1621C>T / c.1621C>T Mice were divided into two groups. One group was subcutaneously injected with AAV-CMV-TadA7.10-nSpG N-inteinN and AAV-CASI-intein C-nSpG C-U6-sgRNA (5 × 10⁻⁶ mcg). 10 (vg / g), another group received subcutaneous injections of AAV-CMV-TadA8e-nSpG N-inteinN and AAV-CASI-intein C-nSpG C-U6-sgRNA double AAV (5×10) 10 The mice were fed for another 7 days. After 7 days, fresh heart and liver tissues were collected from the mice. Genomic DNA was extracted from the heart and liver using a genomic DNA extraction kit and analyzed by amplicon sequencing (AMP-Seq). The specific implementation method is as described in step (7) of this embodiment. The results showed that the editing efficiency of ABE7.10 on the target site (c.1621T) in the heart and liver was about 0.5% and 3%, respectively, while the editing efficiency of ABE8e on the target site (c.1621T) in the heart and liver was about 3% and 10%, respectively. The editing efficiency on the bystander site (c.1619T) was less than 0.2% (e.g., vg / g). Figure 4 (As shown in B).
[0082] Conclusion: Among the base editors ABE7.10 and ABE8e, ABE8e is the superior choice. Using the combination of sgRNA1 and ABE8e can improve editing efficiency at the target site (c.1621T) while reducing editing efficiency at the bystander site (c.1619T).
[0083] Therefore, the present invention utilizes the aforementioned vector for correcting LMNA cardiomyopathy pathogenic mutations and its application to solve the problem of the lack of precise and effective treatment methods for cardiomyopathy caused by LMNA gene mutations.
[0084] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and not to limit them. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can still be made to the technical solutions of the present invention, and these modifications or equivalent substitutions cannot cause the modified technical solutions to deviate from the spirit and scope of the technical solutions of the present invention.
Claims
1. An sgRNA, characterized in that: Including sgRNA1, whose nucleotide sequence is shown in SEQ ID NO.1; It also includes scaffold RNA linked to the 3' end of sgRNA1, the nucleotide sequence of which is shown in SEQ ID NO.2; The target binding region sequence of the sgRNA1 is the exon 10 sequence of the LMNA gene containing the LMNAc.1621C>T mutation in humans and / or mice; the human sequence is shown in SEQ ID NO.3, and the mouse sequence is shown in SEQ ID NO.
4. The sgRNA1 reduces the bystander effect at the LMNA c.1619T site, and the editing efficiency of the sgRNA1 at the bystander site c.1619T is less than 0.2%.
2. The use of the sgRNA as described in claim 1 in the preparation of a drug for correcting pathogenic mutations in LMNAc.1621C>T.
3. A single-base editing plasmid vector, characterized in that: (1) A gene containing a U6 promoter that expresses the sgRNA as described in claim 1; (2) It also contains the gene that expresses the adenine monobase editor ABE.
4. A single-base editing AAV vector, characterized in that: (1) A gene containing a U6 promoter that expresses the sgRNA as described in claim 1; (2) It also contains the gene that expresses the adenine monobase editor ABE; (3) It also contains an AAV capsid with cardiac affinity, selected from one or more of AAV2i8, AAV1, AAV6, AAV8, AAV9, and MyoAAV.
5. A single base editing vector, characterized in that, It consists of two carriers: (1) A vector contains a promoter, a TadA mutant, an nSpCas9 mutant N-terminus, and a coding sequence for intein N; (2) Another vector contains a promoter, intein C, an nSpCas9 mutant C-terminus, and the sgRNA sequence as described in claim 1.
6. The carrier according to claim 5, characterized in that: (1) The promoter sequence is selected from one or more of the CMV, CASI, Tnt4, Myl2, and U6 promoters; the CMV promoter sequence is shown in SEQ ID NO.5, the CASI promoter sequence is shown in SEQ ID NO.6, the Tnt4 promoter sequence is shown in SEQ ID NO.7, the Myl2 promoter sequence is shown in SEQ ID NO.8, and the U6 promoter sequence is shown in SEQ ID NO.9; (2) The coding sequence of the TadA mutant is selected from either TadA7.10 or TadA8e; wherein the coding nucleic acid sequence of TadA7.10 deaminase is shown in SEQ ID NO.10, and the coding nucleic acid sequence of TadA8e is shown in SEQ ID NO.11; (3) The coding sequence of the nSpCas9 mutant is selected from one or more of the nSpG, nNG, or nSpRY genes; the N-terminal coding sequence of nSpG is shown in SEQ ID NO.12, and the C-terminal coding sequence of nSpG is shown in SEQ ID NO.13; the N-terminal coding sequence of nNG is shown in SEQ ID NO.14, and the C-terminal coding sequence of nNG is shown in SEQ ID NO.15; the N-terminal coding sequence of nSpRY is shown in SEQ ID NO.16, and the C-terminal coding sequence of nSpRY is shown in SEQ ID NO.17; (4) The Intein N coding sequence is shown in SEQ ID NO.18; the Intein C coding sequence is shown in SEQ ID NO.19; (5) The nSpCas9 mutant has its coding sequence split into N-terminal and C-terminal sequences at the nucleic acid sequences corresponding to amino acid positions 713 and 714, and then linked to intein N and intein C sequences respectively. In the cell, it is recombined to produce the full-length ABE protein through the intein trans-splicing process.
7. The use of the vector as described in claim 3, 4 or 5 in the preparation of a drug for correcting pathogenic mutations in the LMNA gene.
Citation Information
Patent Citations
Targeted base editing of the USH2a gene
US20230159913A1
Base editing for treating hutchinson-gilford progeria syndrome
WO2020051360A1
